Imeik Technology Development (300896) Fundamentals 2026 — P/E 28.6x, Revenue Analysis | SniperIQ
Imeik Technology Development (300896) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥32.9B, trading at ¥108.80 on the SHZ. This SniperIQ fundamentals page covers Imeik Technology Development's valuation (P/E 28.6x, P/B 4.2x), profitability (net margin 47.3%), revenue (¥2.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Imeik Technology Development's market cap?
Imeik Technology Development (300896) has a market capitalization of approximately ¥32.9B, trading at ¥108.80 on the SHZ. Market cap moves with the live share price.
What is Imeik Technology Development's P/E ratio?
Imeik Technology Development's trailing twelve-month P/E ratio is 28.6x, with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Imeik Technology Development?
Imeik Technology Development runs a net profit margin of 47.3%, a gross margin of 91.7%, and an operating margin of 53.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Imeik Technology Development generate?
Imeik Technology Development reported revenue of ¥2.4B for fiscal year 2025, with net income of ¥1.3B and earnings per share (EPS) of 4.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Imeik Technology Development pay a dividend?
Imeik Technology Development offers a trailing dividend yield of about 1.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Imeik Technology Development financially healthy?
Imeik Technology Development carries a debt-to-equity ratio of 0.03x and a current ratio of 7.21x, with a market beta of 0.72. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Imeik Technology Development a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Imeik Technology Development (300896) the key facts are: market cap ¥32.9B, P/E 28.6x, revenue ¥2.4B, 52-week range 83.36-202.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Imeik Technology Development's full fundamentals live
Get Imeik Technology Development's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.